🔎 Trials Near Me

Home › Glioma › Maryland › Baltimore

Glioma clinical trials in Baltimore, MD

6 studies for Glioma are looking for participants at sites in and around Baltimore (within about 30 miles). Open a study to see who can join and how to contact the study team.

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

RecruitingPhase 1/2
  • Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
12 Months – 21 Years · All sexes · Updated Sep 30, 2026 · NCT05099003

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

RecruitingPhase 2
  • Johns Hopkins Sidney Kimmel Cancer Center - Baltimore, Baltimore
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07326566

Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

RecruitingPhase 1
  • John Hopkins University, Baltimore
Ages 1 to 25 · All sexes · Updated Aug 18, 2026 · NCT04485559

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

RecruitingPhase 2
  • The John Hopkins Hospital, Baltimore
Ages 8 and older · All sexes · Updated Jul 27, 2026 · NCT05503797

LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)

Recruiting
  • Maryland Proton Treatment Center, Baltimore
  • University of Maryland Greenebaum Cancer Center, Baltimore
  • Baltimore Washington Medical Center, Glen Burnie · 9 mi away
  • and 1 more
Ages 18 and older · All sexes · Updated May 6, 2026 · NCT04699773

Hyperpolarized 13C-pyruvate Metabolic MRI With Infiltrating Gliomas

RecruitingPhase 1
  • Rosy Njonkou Tchoquessi, Baltimore
Ages 18 to 80 · All sexes · Updated Sep 22, 2025 · NCT04772456

Glioma trials in other cities

Other studies in Baltimore

From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.